[go: up one dir, main page]

CO2022010592A2 - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CO2022010592A2
CO2022010592A2 CONC2022/0010592A CO2022010592A CO2022010592A2 CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2 CO 2022010592 A CO2022010592 A CO 2022010592A CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2
Authority
CO
Colombia
Prior art keywords
splenomegaly
methods
treatment
therapeutic methods
treating
Prior art date
Application number
CONC2022/0010592A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CO2022010592A2 publication Critical patent/CO2022010592A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
CONC2022/0010592A 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia CO2022010592A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CO2022010592A2 true CO2022010592A2 (es) 2022-10-31

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010592A CO2022010592A2 (es) 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia

Country Status (15)

Country Link
EP (2) EP4000624A1 (es)
JP (1) JP7771064B2 (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (3) MA57226B1 (es)
MX (1) MX2022008490A (es)
TN (1) TN2022000185A1 (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA57226B1 (fr) * 2020-01-08 2023-06-28 Telios Pharma Inc Méthodes de traitement d'une splénomégalie
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
IL309238A (en) * 2021-06-16 2024-02-01 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative tumors
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
JP2025527431A (ja) * 2022-08-25 2025-08-22 ビーワン メディシンズ ワン ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
US20150148345A1 (en) 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
LT3179991T (lt) * 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN112313214A (zh) 2018-06-19 2021-02-02 默克专利有限公司 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
MA57226B1 (fr) * 2020-01-08 2023-06-28 Telios Pharma Inc Méthodes de traitement d'une splénomégalie

Also Published As

Publication number Publication date
KR20220130151A (ko) 2022-09-26
WO2021142257A1 (en) 2021-07-15
MA57226B1 (fr) 2023-06-28
MA63848A1 (fr) 2024-04-30
IL294582A (en) 2022-09-01
CR20220374A (es) 2023-01-25
MA69153A1 (fr) 2025-07-31
AU2021205484A1 (en) 2022-08-18
CA3164063A1 (en) 2021-07-15
JOP20220168A1 (ar) 2023-01-30
MA57226A1 (fr) 2023-02-28
MA63848B1 (fr) 2024-10-31
BR112022013646A2 (pt) 2022-10-04
EP3980069A1 (en) 2022-04-13
JP7771064B2 (ja) 2025-11-17
JP2023509968A (ja) 2023-03-10
EP3980069A4 (en) 2022-08-17
CN114423457A (zh) 2022-04-29
EP4000624A1 (en) 2022-05-25
TN2022000185A1 (en) 2024-04-01
MX2022008490A (es) 2022-10-13

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020009773A (es) Terapia de combinacion.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
CO2020014599A2 (es) Métodos para tratar cáncer
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
MX393452B (es) Tratamiento de los trastornos depresivos.
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
EP4438048A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES
EP4000609A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BR112019022676A2 (pt) método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar